Considerations on Utilization of the Platform-based Approach in Non-Clinical Safety Evaluation of mRNA-LNP Vaccines for Prevention of Infections — PMDA Early Consideration Summary

In Plain Language

The document considers whether safety information from an already approved messenger RNA–lipid nanoparticle (mRNA-LNP) vaccine can support the non-clinical safety evaluation of a new vaccine made using the same production platform. A platform-based approach (PFA) may be considered when the new product meets specified conditions relating to its manufacturer, production process, formulation, product specifications, and impurities. The approach does not mean that every part of the new vaccine can be assessed by relying on the approved product’s studies: the new vaccine’s antigen proteins and the immune responses they may produce need their own consideration. PMDA describes ways existing study results may support assessment of LNPs, mRNA, and impurities, while also identifying circumstances where the new product should be evaluated individually. The document’s purpose is to support vaccine development and limit animal studies to the extent scientifically justified, while treating safety in humans as an essential prerequisite.

What This Guidance Covers

The document presents PMDA’s views on using a PFA in the non-clinical safety evaluation of mRNA-LNP vaccines intended to prevent infections. It focuses on a new vaccine developed by a manufacturer that already has mRNA-LNP vaccines approved for marketing in Japan, where the new vaccine will be produced using the same platform as those approved vaccines. In the document’s terminology, the platform involves established steps for in vitro transcription, purification, and LNP encapsulation.

Scope is conditional, not automatic. The new vaccine’s platform manufacturing should have a quality target product profile (QTPP) in place, with critical quality attributes (CQAs) identified and robustness assured. In principle, the new product should use the same formulation as the approved vaccines, including the same LNP composition, RNA content, and type of modified nucleic acids. “In principle, its final-product specifications should also be the same, except for the altered base sequence of the mRNA active substance and the resulting altered quality attributes.” “In principle, its impurity profile should be equivalent to or less significant than that of the approved vaccines, both qualitatively and quantitatively; apart from impurities associated with the altered mRNA base sequence, new impurities not found in the approved vaccines should not be expected.”

The document says its considerations may apply to vaccines with similar formulation, specifications, or impurity profile, but applicability will be determined on a case-by-case basis. It also identifies differences in LNP or active-substance quality attributes, impurity profiles, or specifications as situations requiring case-by-case consideration. It does not say that the PFA can be applied to every mRNA-LNP vaccine or that the new vaccine’s complete safety evaluation can be replaced by studies of an approved vaccine.

Why It Matters

The document describes two related aims: facilitating effective development of vaccines for prevention of infections and keeping animal studies to the minimum extent scientifically justified. It notes the global trend toward reducing animal studies and the public-health importance of developing vaccines against both continuing and potential infectious-disease threats. It also explains that Japan’s reference guideline for non-clinical studies of vaccines did not reflect experience with the commercialization and approval review of mRNA-LNP vaccines to date. In practice, evaluation had been performed according to the characteristics of individual products, with reference to that guideline and other relevant international guidance.

A platform approach may make it possible to use relevant information from an approved vaccine where the products share important features. However, the document emphasizes that the antigen proteins encoded by the new vaccine’s mRNA may differ, and that the level or nature of the immune response may differ as well. Animal studies also have limitations in detecting certain unintended effects of exogenous antigen proteins in human tissues and organs. The document therefore balances the potential to use existing data with the need to evaluate new-product concerns and maintain safety in humans as an essential prerequisite.

Key Recommendations

1. First establish that the new vaccine fits the stated scope. Before using an approved vaccine’s non-clinical safety study results to support a new vaccine, confirm that the new product meets the scope conditions described in the document. Those conditions include an existing approved mRNA-LNP vaccine from the same manufacturer in Japan, use of the same platform, and the quality, formulation, specification, and impurity characteristics set out above.

2. Use approved-vaccine data for LNP safety evaluation only under the stated condition. If the new and approved vaccines use LNPs with the same composition—that is, the same types of lipid components at the same ratio—toxicity study results for the approved vaccines can be used to evaluate the LNPs in the new vaccine from the viewpoint of off-target toxicity. If the proposed dosage regimen in practical settings for the new vaccine exceeds that of the approved vaccines, the doses and dosing frequencies used in the approved vaccines’ toxicity studies should be confirmed to be equal to or greater than those for the new vaccine in practical settings.

3. Consider whether mRNA data can support assessment of the new active substance. If the new and approved vaccines use active substances made of the same types of nucleic acids—for example, both contain the same modified nucleic acids, or both contain only non-modified nucleic acids—approved-vaccine toxicity study results can be used to evaluate the new vaccine’s mRNA, including biological degradation products or nucleic acids derived from the mRNA, from the viewpoint of off-target toxicity. The same dosage-regimen considerations described for LNPs apply.

4. Assess the new antigen proteins rather than carrying over the approved vaccine’s results. The document says that toxicity study results from approved mRNA-LNP vaccines cannot be used to evaluate the antigen proteins encoded by the new vaccine’s mRNA. From the viewpoint of on-target toxicity, safety concerns associated with the immune response to the new vaccine should be ruled out by prediction based on non-clinical pharmacology study results for that vaccine. From the viewpoint of off-target toxicity, epidemiologic information about the infection the new vaccine is intended to prevent should be collected and reviewed, including information about immune-mediated reactions after that infection in humans. The document notes that individual non-clinical safety studies of the new vaccine may need to be considered, for example, if adequate epidemiologic information about the infection is lacking.

5. Use approved-vaccine data for impurity assessment only within the described scope. If the new vaccine meets the scope conditions, approved-vaccine toxicity study results can be used to evaluate impurities in the new product from the viewpoint of off-target toxicity. The dosage-regimen considerations for LNPs and mRNA also apply to this evaluation.

6. Explain relevant differences when considering a case-specific application. If the LNPs, active substances, or impurity profile differ in quality attributes from those of the approved vaccines, or if specifications have changed, the applicability of the PFA should be determined case by case. If the approach is applied in such a case, the difference or change should be explained to rule out potential resulting safety concerns in humans.

7. Provide the justification at the relevant development stage. When approved-vaccine non-clinical safety results are used as data supporting the start of clinical trials, the new vaccine should be confirmed to meet the scope conditions and the non-clinical safety evaluation should be justified with reference to the document’s basic considerations at the time of the initial clinical trial notification. When such results support a marketing-approval application, the scope conditions should again be confirmed and the adequacy of the new vaccine’s non-clinical safety evaluation should be explained in view of clinical-study safety information and scientific knowledge available at the time of the application.

Practical Implications

Interpretation: For sponsors, the PFA is best understood as a structured justification for using relevant existing data, not as a blanket exemption from assessing a new vaccine. A development team would need to compare the proposed product with the approved platform vaccine across the specific features identified by the document and make clear where they match and where they differ. That comparison helps establish whether the shared platform information is relevant to each safety question.

For non-clinical teams, the document points toward separating the assessment by product component and type of toxicity. Existing results may support evaluation of LNPs, mRNA-related material, and impurities if the relevant conditions are met. The antigen protein is different: the new vaccine’s immune response and possible unintended effects call for product-specific consideration informed by pharmacology and epidemiologic information. The document does not specify a single study package for every new vaccine; it says individual studies may need to be considered in some situations.

For clinical operations and regulatory teams, the timing of the rationale matters. When the evidence supports starting clinical trials, the initial clinical trial notification stage is where the document says to confirm scope and justify the non-clinical evaluation. At marketing-approval application, the explanation should take account of safety information from clinical studies and scientific knowledge available at that time. These are distinct points in development, and the basis for the assessment may need to reflect information accumulated between them.

For quality and manufacturing teams, the scope conditions make platform comparability relevant to the safety rationale. In particular, the document calls attention to formulation, specifications, quality attributes, robustness, and the impurity profile. If a difference or specification change is present, it should not be obscured by the general claim that the product uses the same platform; its potential safety implications should be explained if the PFA is applied.

Technical Details

The document distinguishes on-target toxicity from off-target toxicity. On-target toxicity is toxicity in vaccine recipients attributable to excessive humoral or cellular immune response to antigen proteins expressed by the vaccine’s mRNA. Off-target toxicity is toxicity caused by vaccine constituents other than on-target toxicity; the document gives LNP toxicity, impurity toxicity, and unintended toxicity attributable to expressed antigen proteins as examples. This distinction explains why the document treats LNPs and mRNA differently from the new antigen proteins.

The reasoning can be followed in stages:

These steps are not a numerical algorithm: the document provides no formula or universal threshold for deciding whether two products are sufficiently alike. It describes conditions and lines of assessment to be considered, with case-by-case decisions where specified. Its scope also makes clear that the PFA concerns use of existing non-clinical safety information; the document separately calls for consideration of clinical-study safety information when explaining adequacy at marketing-approval application.

Who Should Read It

This document is relevant to professionals working on non-clinical safety, vaccine pharmacology, toxicology, quality, manufacturing, clinical development, and regulatory submissions for mRNA-LNP vaccines intended to prevent infections. It may be particularly useful to teams planning a new vaccine on a platform used for an mRNA-LNP vaccine already approved in Japan, and to reviewers or study teams assessing whether existing safety information is applicable. It is also relevant when teams are preparing the rationale for an initial clinical trial notification or a marketing-approval application, especially where product-specific differences need to be addressed.

Official PMDA Source

• Official title: Considerations on Utilization of the Platform-based Approach in Non-Clinical Safety Evaluation of mRNA-LNP Vaccines for Prevention of Infections (Early Consideration)
• Issuing body: Pharmaceuticals and Medical Devices Agency, Office of Vaccines and Blood Products
• Date on the document: February 6, 2026
• PMDA PDF: Official PMDA document (PDF)
• PMDA list page: PMDA Early Consideration documents

Source: Pharmaceuticals and Medical Devices Agency (PMDA) website, PMDA Early Consideration documents. This page was created by editing and summarising the PMDA document.

Consult the official document; this summary does not replace it. PMDA provides the English version for reference purposes only, and if it differs from the Japanese original, the Japanese original prevails.

Related Clinical Biostats Resources

• All Clinical Biostats tutorials — Browse other educational summaries, including material on non-clinical studies and vaccine development.
• Statistical Calculators — Access calculators that may assist with statistical work in clinical research.